BioSpace News Archive

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its first quarter 2022 financial results on Tuesday, May 10, 2022.

Moderna, Inc. today announced new clinical data on its bivalent COVID-19 booster platform including data on the Company’s first bivalent booster candidate, mRNA-1273.211.

Plus Therapeutics, Inc. announced that it will discuss new data in an oral presentation at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting, being held June 11-14, 2022, in Vancouver, British Columbia, Canada.

Microbix Biosystems Inc. announces it will be presenting performance results of its quality assessment products that support molecular-diagnostic screening-tests for respiratory viruses at two industry congresses – “Labquality Days” in Helsinki, Finland April 20-21, 2022 and “ECCMID 2022” in Lisbon, Portugal, April 23-26, 2022.

BioXcel Therapeutics, Inc. announced the formation of wholly-owned subsidiary OnkosXcel Therapeutics, Inc. to develop transformative medicines in oncology.

Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead program ADI-001.

Potrero Medical announced that the Accuryn Monitoring Solution will be showcased in presentations during the Society of Critical Care Medicine (SCCM) virtual meeting April 18-21, 2022.

Aurinia Pharmaceuticals Inc. today, affirmed its commitment to individuals living with the systemic lupus erythematosus (SLE) and lupus nephritis (LN) through the sponsorship of charitable grants to establish or expand community-focused patient navigator programs.

Quipt Home Medical Corp. is very pleased to announce that it has acquired Good Night Medical, LLC, a business with operations across seven U.S. states, reporting unaudited trailing 12-month annual revenues of approximately $7.5 million ‎and with anticipated Adjusted EBITDA of $1.5 million post integration.

NextCure, Inc. announced the publication of a paper titled “Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1-mediated tumor eradication” in the Journal of Clinical Investigation.